ALGS

Rating neutralTentativeAI MemoPost-earnings T+3

Aligos Therapeutics

As of 2026-05-09/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Second B-SUPREME interim analysis in 2H 2026 • 2026-09-15

Expected move: +10%

Biggest risk

Q1 still showed a $23.0 million net loss, cash/investments fell to $54.9 million from $77.8 million at year-end, and R&D expense rose to $23.4 million as Phase 2 spending increased [#8-K-2026-05-07]. The 10-Q kept going-concern language, so the financing overhang still dominates the pre-topline setup.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

The post-earnings update was incrementally better than the April baseline: B-SUPREME remains active after clearing futility, the Amoytop transaction adds a $25 million upfront cash component, and management now guides runway into the fourth quarter of 2026 rather than only into the third quarter. That supports a monitoring thesis instead of a fresh deterioration call.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-09

Base target

p=45%

Bull target

$10

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway and financing watch moved out but not removed
2027 B-SUPREME topline remains the main value driver
The post-earnings update was incrementally better than the April baseline: B-SUPREME remains active after clearing futility, the Amoytop transaction adds a $25 million upfront cash component, and management now guides runway into the fourth quarter of 2026 rather than only into the third quarter.

BearKey bullets

Management said current cash is expected to fund operations only into the fourth quarter of 2026, inclusive of the expected Amoytop upfront, leaving a financing or partnering need ahead of 2027 topline data [#8-K-2026-05-07].
No trustworthy post-earnings analyst target or rating revision flow was confirmed in this follow-up run, and the public peer set remains imperfect because the closest HBV comparators differ by modality, scale, or private-company status.
R&D expense rose year over year because of higher third-party spending for the pevifoscorvir sodium Phase 2 trial, so burn remains elevated [#8-K-2026-05-07].

WatchKey bullets

Second B-SUPREME interim analysis in 2H 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $6 (p=45%)

Bull/Bear spread: +90% / -43%

Vs latest close: Bull +90% · Base +10% · Bear -43%

Scenario probabilities

Bull Target: $10 (p=25%)Base Target: $6 (p=45%)Bear Target: $3 (p=30%)

Commentary

This T+3 follow-up confirms the May 7, 2026 company earnings release and updates the thesis only modestly. The tone improved at the margin because management extended expected runway into Q4 2026 and highlighted the $25 million Amoytop upfront, but the 10-Q still carries going-concern language and the decisive value event remains a 2027 clinical readout. Market reaction was not decisive: the packet anchor was $6.03 on May 7, 2026, and the latest quote checked was about $6.44 on May 9, 2026 UTC, suggesting only a modest post-print bounce. No trustworthy delayed analyst revision signal was confirmed, and peer benchmarking remains tentative because the cleanest public HBV peers are operating comparators rather than close same-scale valuation comps, so this remains a cautious monitoring setup rather than a thesis upgrade.

As of 2026-05-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway and financing watch moved out but not removed
2027 B-SUPREME topline remains the main value driver

Scenarios

Bull Target (Scenario probability)

$10 / p=25% prob

Base Target (Scenario probability)

$6 / p=45% prob

Bear Target (Scenario probability)

$3 / p=30% prob

Price $5 as of 2026-06-02

Nearest Scenario: Base (∆ 10%)

Targets vs latest close: Bull +90% · Base +10% · Bear -43%

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-15
Second B-SUPREME interim analysis in 2H 2026
Management said the Phase 2 B-SUPREME study remains ongoing, the first interim analysis cleared futility, the DSMB recommended increasing the HBeAg- sample size to 100 from 74, and the second protocol-defined interim analysis is expected in the second half of 2026 [#8-K-2026-05-07]. A clean update would help offset financing pressure, but the sample-size increase also shows the study needed more power.
Prob 65.00% • Move 24.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Runway and financing watch moved out but not removed
2026-10-01
The May 7 earnings release said cash, cash equivalents and investments were $54.9 million at March 31, 2026 and are expected to fund planned operations into the fourth quarter of 2026, inclusive of the expected $25 million Amoytop upfront, while the 10-Q still says recurring losses and negative cash flows raise substantial doubt about continuing as a going concern [#8-K-2026-05-07] [#10-Q-2026-05-07]. That modestly improves near-term flexibility versus the prior Q3 runway framing, but it still leaves a likely financing or partnering decision before the 2027 clinical readout.
Prob 80% • Move -18% • Priced-in 70%

Long-term Catalysts

Months to a year

2027 B-SUPREME topline remains the main value driver
2027-06-30
Aligos reaffirmed that topline data for both HBeAg- and HBeAg+ B-SUPREME cohorts are expected in 2027, keeping the HBV program as the core long-duration upside case [#8-K-2026-05-07]. The setup remains binary because the company still appears likely to need capital before that readout.
Prob 40% • Move 80% • Priced-in 25%

Risks

Management said current cash is expected to fund operations only into the fourth quarter of 2026, inclusive of the expected Amoytop upfront, leaving a financing or partnering need ahead of 2027 topline data [#8-K-2026-05-07].
No trustworthy post-earnings analyst target or rating revision flow was confirmed in this follow-up run, and the public peer set remains imperfect because the closest HBV comparators differ by modality, scale, or private-company status.
R&D expense rose year over year because of higher third-party spending for the pevifoscorvir sodium Phase 2 trial, so burn remains elevated [#8-K-2026-05-07].
The 10-Q still says recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern [#10-Q-2026-05-07].
The DSMB recommended increasing the HBeAg- cohort sample size to 100 from 74, indicating the study needed more participants to preserve statistical power [#8-K-2026-05-07].

Peers

Symbol	Summary
ASMB	Assembly Biosciences is the closest public operating comparator in this peer set because Aligos identifies Assembly among companies developing CAM-Es for HBV, directly overlapping with Aligos' HBV capsid-assembly-modulator focus [#10-K-2026-03-05].
ABUS	Arbutus is a relevant HBV therapeutic peer because Aligos lists Arbutus among companies with oligonucleotide agents in clinical development for chronic HBV infection; modality differs, but the clinical disease area and competitive investor narrative overlap [#10-K-2026-03-05].
IONS	Ionis is a larger and less valuation-comparable HBV landscape peer because Aligos names Ionis, together with GSK, among companies developing oligonucleotide agents for chronic HBV infection; it is useful for competitive context rather than small-cap valuation comparison [#10-K-2026-03-05].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-09

AI Stock Memo: ALGS - Aligos Therapeutics - RankAlpha